1.1
Deep Ensemble for Recognition of Malignancy (DERM, an artificial intelligence [AI] technology) can be used within teledermatology services in the NHS during the evidence generation period as an option to assess and triage skin lesions in adults referred to the urgent suspected skin cancer pathway. It can only be used:
-
if the evidence outlined in the evidence generation plan is being generated
-
once it has appropriate regulatory approval including NHS England's Digital Technology Assessment Criteria (DTAC) approval.